"Summer, Summer almost here. Let’s give summer a big fat cheer! Of this fact, I’m surely clear: summer is the best time of year." ~Tim Rasinski Many people love the warm sun, [...]
On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
The heart is at the center of the cardiovascular system, the main function of which is to pump blood throughout the body, providing tissue and organs with the oxygen and nutrients they need. To ensure [...]
Cancer patients are surviving longer thanks to breakthrough treatments like targeted therapies. With the additional longevity, however, is the responsibility to consider other health issues that may manifest, either due to treatments such as radiation, [...]
American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR). ASCO plans should increase patient access to off-label drugs and match patients with [...]
Sutent 37.5 mg Ease of use and lower costs may be on the horizon for Sutent patients who are currently on a 37.5 milligram prescription. Available now, Pfizer has released a new [...]
A recent study published in Oncology Letters, discusses the importance of effective therapy management of sunitinib (Sutent)
I’ve been thinking a lot about writing this article. The last thing I want to do is cause worry or pain to anyone reading this. Then I thought of all the people who could possibly benefit in the future from knowing ahead of time what we didn’t know at the time we needed to know it.
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.
The Life Raft Group surveyed patients and physicians about dosing options for the drug Sutent (sunitinib) to follow up on a 2011 study that showed that patients on a continuous dose exhibited better clinical outcomes than those on the standard four-week on, two-week off dosing regimen.